A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
Evopoint Biosciences Inc.
Theolytics Limited
Immatics US, Inc.
Bristol-Myers Squibb
Genmab
Imunon
Beijing Biotech
Genmab
National Institutes of Health Clinical Center (CC)
CanariaBio Inc.
Mayo Clinic
AstraZeneca
Incyclix Bio
Compugen Ltd
858 Therapeutics, Inc.
Radiopharm Theranostics, Ltd
AstraZeneca
Terremoto Biosciences Inc.
University of Louisville
Artios Pharma Ltd
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Case Comprehensive Cancer Center
Beijing Biotech
Filamon LTD
Ensem Therapeutics
Eisai Inc.
PMV Pharmaceuticals, Inc
AstraZeneca
University of California, Irvine
Sun Yat-sen University
The Netherlands Cancer Institute
NeoImmuneTech
Nanjing Leads Biolabs Co.,Ltd
Qilu Pharmaceutical Co., Ltd.
Tubulis GmbH
Eli Lilly and Company
AstraZeneca
Genmab
Children's Oncology Group
AstraZeneca
A2 Biotherapeutics Inc.
University of Chicago
AstraZeneca
M.D. Anderson Cancer Center
Arvinas Inc.
BioInvent International AB
University of Florida
Essen Biotech
Essen Biotech